[Skip to Content]
[Skip to Content Landing]
Views 63
Citations 0
Comment & Response
May 15, 2017

Could Albumin be a Biomarker to Monitor the Effect of Intravenous Immunoglobulin on Guillain-Barré Syndrome?—Reply

Author Affiliations
  • 1Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
  • 2Department of Neurology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
JAMA Neurol. Published online May 15, 2017. doi:10.1001/jamaneurol.2017.0566

In Reply We appreciate the interest of Wang and Zhang in our study.1 They raise several questions about the interpretation of our finding that serum albumin levels in Guillain-Barré syndrome (GBS) treated with intravenous immunoglobulin are a potential biomarker to monitor the treatment response and predict outcome. Some of their points were discussed previously.1,2

First Page Preview View Large
First page PDF preview
First page PDF preview
×